Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06614543

Feasibility Testing of Plant-Based Meal Replacement Products Made With Manitoba Crop Ingredients for Weight Loss and Diabetes Remission

The goal of this clinical trial is to advance the development of the WI meal replacements by evaluating the acceptance and feasibility of the meal replacements within the Wellness Institute's Weight Loss Clinic program (WLC). The main questions it aims to answer are:

* To determine whether the incorporation of WI meal replacements into their weight loss clinic design is feasible. * To determine whether weight loss is supported by a plant-based meal replacement. * To assess efficacy of the meal replacements by measuring changes in lifestyle behaviours and risk factors for chronic disease compared to non-meal replacement weight loss program members. * To assess remission of diabetes and pre-diabetes.

Researchers will compare the WLC program plus meal replacements to the WLC program without the meal replacements to evaluate the implementation of the meal replacements into the WLC.

Participants will follow their WLC program for 16 weeks, and those in the intervention group will begin their meal replacements. Participants will have a choice on what type of meal replacement they will consume each day (either a bar or a shake) and will record this in the product consumption log.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Seven Oaks Hospital Chronic Disease Innovation Centre

Winnipeg, Manitoba, R2V 3M3, Canada

Location contact

Dr Rebecca Mollard, PhD

SUB_INVESTIGATOR

Kathy Cherepak, BSc

CONTACT

[email protected]

204-631-3834

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female, aged 18 years or above
  • Live within the province of MB
  • Ability to give written informed consent in English.
  • Enrolled in the Wellness Institute Weight Loss Clinic

Exclusion criteria

  • Female participant who is pregnant, lactating or planning pregnancy during the course of the program.
  • Participants with known allergies to the meal replacement ingredients
  • Has an active eating disorder

Treatment and study plan

Meal Replacement

Dietary Supplement

These meal replacements provide plant-based protein, fibre and fatty acids that have been shown to have health benefits related to chronic disease.

Primary outcomes

  1. Feasibility of incorporating the WI meal replacements into their weight loss clinic design.

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Feasibility will be demonstrated if the following five criteria are met:

    • Eligibility to randomization ratio is greater than 0.5, calculated as the ratio of individuals within the WI WLC program who were randomized to the trial to the number eligible to participate who were approached to participate.
    • The percentage of participants who complete the 16-week program in the meal replacement arm is equivalent (plus or minus 10%) or greater than the standard arm.
    • Follow up of greater than 85% of participant outcomes.
    • Adherence to the meal replacement intervention calculated by consumption of greater than 75% dispensed products as documented in the Product Consumption Log
    • Product Acceptability using an Exit Questionnaire consisting of a 9-point hedonic box scale to assess mean acceptability values of 6 or greater (like at least slightly) in 75% or more of the participants.

Secondary outcomes

  1. Changes in Body Weight

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Body weight will be measured in kg to the nearest 0.1 kg by an exercise professional.

  2. Changes in Waist Circumference

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Waist circumference in cm will be measured to the nearest 0.1 cm at the umbilicus, between the last rib and iliac crest using a fibreglass tape measured by an exercise professional.

  3. Changes in BMI

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Body Mass Index will be calculated using the formula BMI = kg/m2; where kg is the weight in kilograms and m2 is height in metres squared.

  4. Cardiovascular Assessment

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Using the Framingham Risk Score, cardiovascular risk will be calculated based on age, HDL-C, total cholesterol, systolic blood pressure, smoking status, and diabetes status to determine the participant's 10-year risk of cardiovascular disease and identification of metabolic syndrome.

  5. Changes is Quality of Life

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Quality of life will be measured through the SF-36 quality of life questionnaire. The SF-36 measures nine areas: physical functioning, role functioning (emotional), role functioning (physical), energy/fatigue, emotional well-being, social functioning, pain, general health, and health change. A higher score indicates greater levels of quality of life.

  6. Changes in Medication

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Changes in medications, dose, unit and frequency will be captured to assess remission of diabetes and pre-diabetes.

  7. Changes in HemaglobinA1C

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Changes in hemaglobinA1C will be used to assess remission of diabetes and pre-diabetes. Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the hemoglobin A1C as a percentage according to their established protocols.

Other outcomes

  1. Changes in Systolic Blood Pressure

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Systolic blood pressure in mmHg is measured in triplicate, on the non-dominant arm in a sitting position by an exercise professional using a validated oscillometric blood pressure monitor.

  2. Changes in Diastolic Blood Pressure

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Diastolic blood pressure in mmHg is measured in triplicate, on the non-dominant arm in a sitting position by an exercise professional using a validated oscillometric blood pressure monitor.

  3. Changes in Heart Rate

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Heart rate in beats per minute is measured in triplicate, on the non-dominant arm in a sitting position by an exercise professional using a validated oscillometric blood pressure monitor.

  4. Changes in Physical Activity

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Measured using the International Physical Activity Questionnaire - Short Form - (IPAQ-S)

  5. Change in Physical Activity Behaviour Patterns

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Assessed using total active minutes per day as measured by multi-directional accelerometry for 5 days. Participants will be asked to wear the accelerometer at all times.

  6. Changes in Dietary Intake Behaviours

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Dietary intake behaviours will be measured through The Mindful Eating Questionnaire. The Mindful Eating Questionnaire recognizing patterns of overeating or eating in response to stress, boredom, or other emotions. Scoring is based on five categories, which include Awareness (being aware of how food looks, tastes and smells); Distraction (focusing on other things while eating); Disinhibition (eating even when full); Emotional Response (eating in response to sadness or stress); and External Cues (eating in response to environmental cues, such as advertising)

  7. Changes in Dietary Intake Behaviours

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Changes in dietary intake behaviours will be measured through the Three Factor Eating Questionnaire which is comprised of 18 items, measuring uncontrolled eating, restrained eating and emotional eating. The higher the score represents more dependency to cognition, stress or emotion the eating patterns.

  8. Changes in Dietary Intake - Number of Meals

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Number of meals will be captured with a meal being defined as food intake greater than 500 kcal. Dietary intake will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

  9. Changes in Dietary Intake - Number of Snacks

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Number of snacks will be captured with a meal being defined as food intake less than 500 kcal. Dietary intake will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

  10. Changes in Dietary Intake - Energy

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Energy will be measured in kCals and will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

  11. Changes in Dietary Intake - Protein

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Protein will be measured in grams and will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

  12. Changes in Dietary Intake - Fat

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Fat will be measured in grams and will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

  13. Changes in Dietary Intake - Available Carbohydrates

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Available carbohydrates will be measured in grams and will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

  14. Changes in Dietary Intake - Fibre

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Fibre will be measured in grams and will be captured using the RxFood app. RxFood is a type of AI-driven, image based dietary assessment tool that has already demonstrated clinical benefits in various adult and pediatric clinical settings and in research as a data collection tool. Strong correlation and strength of agreement have been illustrated between RxFood and nutrient estimates from Esha's Research Nutrition analysis software, which is an industry choice for nutritional analysis and regulatory compliance (Jefferson et al, 2020).

  15. Changes in Sleep Patterns

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    An ActiGraph activity monitor will be used to measure sleep quality patterns for 5 days, with participants asked to wear the monitor at all times, including when they sleep.

  16. Changes in Total Cholesterol

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

  17. Changes in High density lipoprotein cholesterol

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

  18. Changes in Low density lipoprotein cholesterol

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

  19. Changes in Triglycerides

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

  20. Changes in Total Cholesterol and High-Density Lipoprotein Cholesterol Ratio

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

  21. Changes in Hemoglobin A1C

    Time frame: At Enrollment (Week 0) and End of Study (Week 16)

    Diagnostic Services of Manitoba will collect and process the participants blood samples and measure the total cholesterol concentration in mmol/L according to their established protocols.

Study contacts

Contact information is provided by the study sponsor or research team.

Dr Dylan MacKay, PhD

CONTACT

[email protected]

204-272-3119

Kathy Cherepak, BSc

CONTACT

[email protected]

204-631-3834

Sponsors and collaborators

Lead sponsor

University of Manitoba

Other

Collaborators

  • Seven Oaks Hospital Chronic Disease Innovation Centre
  • Sustainable Canadian Agricultural Partnership
  • The Wellness Institute

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Sep 26, 2024
Registry last updated
Jun 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.